{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:41:47Z","timestamp":1791463307136,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001342","name":"Department of Science and Technology, Republic of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["MRC-RFA-IFSP-01-2013"],"award-info":[{"award-number":["MRC-RFA-IFSP-01-2013"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lundbeck International"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.schres.2018.11.031","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T02:36:17Z","timestamp":1543545377000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12\u202fmonths"],"prefix":"10.1016","volume":"206","author":[{"given":"H.","family":"Luckhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Phahladira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Asmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Chiliza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2018.11.031_bb4000","series-title":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.11.031_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.schres.2018.11.031_bb0030","first-page":"11","article-title":"Antipsychotic-associated weight gain and clinical outcome parameters","volume":"62","author":"Blin","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.11.031_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1176\/ajp.153.6.817","article-title":"Differential effect of clozapine on weight: a controlled study","volume":"153","author":"Bustillo","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eurpsy.2013.04.003","article-title":"Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology","volume":"29","author":"Chen","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2018.11.031_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2014.12.012","article-title":"Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms","volume":"53","author":"Chien","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.schres.2018.11.031_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eurpsy.2014.11.013","article-title":"Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12\u202fmonths with a first-generation antipsychotic","volume":"30","author":"Chiliza","year":"2015","journal-title":"Eur. Psychiatry."},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1194\/jlr.R009761","article-title":"Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mousemodels","volume":"52","author":"Chrast","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.schres.2018.11.031_bb0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00023210-200721060-00001","article-title":"Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics","volume":"21","author":"Chue","year":"2007","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/08039488.2015.1074283","article-title":"Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?","volume":"70","author":"Chukhin","year":"2016","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.11.031_bb0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis","volume":"106","author":"Coldham","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2018.11.031_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/schbul\/sbq088","article-title":"Disorganization\/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis","volume":"38","author":"Demjaha","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2018.11.031_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnins.2013.00036","article-title":"Serotonin and the regulation of mammalian energy balance","volume":"7","author":"Donovan","year":"2013","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2018.11.031_bb0090","first-page":"453","article-title":"The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study","volume":"24","author":"Dursun","year":"1999","journal-title":"J. Psychiatry Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2018.11.031_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-9964(02)00302-X","article-title":"The factor structure for the positive and negative syndrome scale (PANSS) in recent-onset psychosis","volume":"61","author":"Emsley","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.11.031_bb0100","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/NDT.S50006","article-title":"Etiology of cardiovascular disease in patients with schizophrenia: current perspectives","volume":"11","author":"Emul","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.schres.2018.11.031_bb0105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/YIC.0b013e32834a5bf6","article-title":"The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs","volume":"26","author":"Falissard","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.11.031_bb0110","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) 1994","author":"First","year":"1994"},{"issue":"10","key":"10.1016\/j.schres.2018.11.031_bb0115","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2008.40","article-title":"Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway","volume":"13","author":"Girgis","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2018.11.031_bb0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis","volume":"26","author":"Gressier","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0253-7176.183091","article-title":"Metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents","volume":"38","author":"Grover","year":"2016","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.schres.2018.11.031_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","article-title":"Weight gain induced by clozapine","volume":"5","author":"Hummer","year":"1995","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2018.11.031_bb3000","series-title":"ICH Tripartite Guideline for Good Clinical Practices E6 (R1) June 10","author":"International Conference of Harmonization (ICH)","year":"1996"},{"issue":"2","key":"10.1016\/j.schres.2018.11.031_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40501-014-0010-9","article-title":"Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia","volume":"1","author":"Javitt","year":"2015","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"10.1016\/j.schres.2018.11.031_bb2000","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/705631","article-title":"Utility of PANSS 5-factor models for assessing psychopathology outcomes in clinical programs for persons with schizophrenia","author":"Jerrell","year":"2013","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.schres.2018.11.031_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.schres.2018.11.031_bb0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/cap.2012.0099","article-title":"Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia","volume":"23","author":"Kemp","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.11.031_bb0150","first-page":"102","article-title":"Weight changes during treatment with phenothiazine derivatives","volume":"2","author":"Klett","year":"1960","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.schres.2018.11.031_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0269881112472568","article-title":"Increases in triglyceride levels are associated with clinical response to clozapine treatment","volume":"27","author":"Lally","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"9896","key":"10.1016\/j.schres.2018.11.031_bb0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.schres.2018.11.031_bb0165","first-page":"30368-7","article-title":"Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study","volume":"S0920\u20139964","author":"Lu","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.11.031_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.11.031_bb0175","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0269881108091879","article-title":"Long-term treatment with flupentixol results of a post-marketing surveillance study","volume":"23","author":"Messer","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3371\/CSRP.ORGA.022015","article-title":"Disorganized symptoms predicted worse functioning outcome in schizophrenia patients with established illness","volume":"11","author":"Ortiz","year":"2017","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2018.11.031_bb0185","doi-asserted-by":"crossref","DOI":"10.2174\/157340011795945793","article-title":"The role of orexin system in antipsychotics induced weight gain","volume":"7","author":"Panariello","year":"2011","journal-title":"Curr. Psychiatr. Rev."},{"key":"10.1016\/j.schres.2018.11.031_bb0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF01561635","article-title":"Changes in weight in patients receiving a tranquilizing drug","volume":"32","author":"Planansky","year":"1958","journal-title":"Psychiatr Q."},{"issue":"5","key":"10.1016\/j.schres.2018.11.031_bb0195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1139\/jpn.0733","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2018.11.031_bb0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"11","author":"Raben","year":"2018","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2018.11.031_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2018.11.031_bb0210","first-page":"292","article-title":"Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications","volume":"4","author":"Riordan","year":"2011","journal-title":"Am. Health. Drug. Benefits"},{"issue":"10","key":"10.1016\/j.schres.2018.11.031_bb0215","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2018.11.031_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajp.2013.11.017","article-title":"Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the evidence for \u201cmetabolic threshold\u201d","volume":"8","author":"Sharma","year":"2014","journal-title":"Asian J. Psychiatr."},{"issue":"4","key":"10.1016\/j.schres.2018.11.031_bb0225","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/acps.12388","article-title":"Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia","volume":"132","author":"Solberg","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2018.11.031_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12888-016-1006-3","article-title":"Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study","volume":"16","author":"Solberg","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.11.031_bb0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/eip.12251","article-title":"Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications","volume":"10","author":"Tek","year":"2016","journal-title":"Early. Interv. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2018.11.031_bb1000","first-page":"1661","article-title":"Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotic trial","volume":"16","author":"Terevnikov","year":"2013","journal-title":"Int. J. Neuropharmacol."},{"issue":"B","key":"10.1016\/j.schres.2018.11.031_bb0240","first-page":"157","article-title":"Clozapine and weight gain","volume":"55","author":"Umbricht","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.11.031_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9758\/cpn.2013.11.1.24","article-title":"A longitudinal study of relation between side-effects and clinical improvement in schizophrenia: is there a neuro-metabolic threshold for second generation antipsychotics?","volume":"11","author":"Venkatasubramanian","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.schres.2018.11.031_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00737-003-0010-z","article-title":"Gender-related differences in pharmacological relapse prevention with flupenthixoldecanoate in detoxified alcoholics","volume":"6","author":"Wiesbeck","year":"2003","journal-title":"Arch. Womens Ment. Health"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418306820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418306820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:29:24Z","timestamp":1760297364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418306820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":51,"alternative-id":["S0920996418306820"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.11.031","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12\u202fmonths","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}